Back to results
US 10,254,289 B2Granted
In vitro method for early or differential diagnosis or prognosis of myocardial infarction in a patient
AssigneeB.R.A.H.M.S GmbH
InventorsAndreas Bergmann, Nils Morgenthaler, Jana Papassotiriou, Joachim Struck, Leong L. Ng
Life of this patent
Estimating the term…
Abstract
The invention relates to a method for risk stratification for acute coronary syndrome (ACS), in particular acute myocardial infarction (AMI) and angina pectoris (AP), wherein provasopressin (proAVP) or fragments and partial peptides thereof, in particular copeptin or neurophysin II, is determined by an in vitro diagnosis.
Claims12
An in vitro method for differential diagnosis or prognosis of myocardial infarction in a patient, said method comprising:
- determining in at least one sample of bodily fluid from a patient to be studied the level of copeptin and neurophysin II, wherein said at least one sample of bodily fluid is taken from said patient within the first 6 hours after appearance of symptoms of acute coronary syndrome or myocardial infarction,
- wherein a threshold level of copeptin of 6-20 pmol/L and a threshold level of neurophysin II of 6-10 pmol/L are indicative of differential diagnosis or prognosis of myocardial infarction.
Dependencies are inferred from the claim text.